Treatment

treatment-plan

TREATMENT

The class of inherited variants we discovered and continue to research can help identify the best treatment choices for patients.

curve-up2

Current cancer treatment limitations

Cancer treatments with the whole person in mind

Current cancer treatments focus on simply destroying the cancer, with treatments based on the type, location, stage, and genetics of the tumor alone. This approach to treatment certainly does work, as all those who have been cured of cancer can attest. More people are living longer after their original cancer diagnosis than ever.

However, there is still another problem for cancer patients. Cancer treatments are hard on the human body and often lead to negative side effects. While there are risks of negative side effects with any treatment, medicine needs to move its focus from killing cancer alone to a whole-person view.

Evolution of cancer treatments

whole-person

The good news is that cancer treatment is evolving. We are learning how to fine-tune treatment for each individual.

One way is through genetic testing. While the genetics of the tumor are already tested with current cancer treatment, that doesn't let us see the whole picture. We must also look at a person's individual genetics, not just their tumor's.

cancer-treatment-evolution-no-text

Cancer treatments and genetics

Our research here at MiraKind focuses on genetic testing of the individual's normal genetic code. We have found essential information in a recently discovered part of the DNA, called noncoding DNA.

Your DNA not only builds your body and tells it how to function, but is also intimately involved in overseeing the repair and stress response programs that manage damage to your body and its DNA. Noncoding DNA is the guide behind these programs.

People have differences (variations) in their DNA that make them unique. If these variations are in important parts of the noncoding DNA, they can impact how the programming works, and thus how the body responds to damage.

snp2-4

At the beginning of our research, we discovered the first variant in a specific section of the noncoding DNA. As our research continued, we found many more, and these type of variants are now referred to as "mirSNPs". MirSNPs seem to predict how a person responds to specific cancer treatments by telling us how well they will repair damage from these treatments, as well as how their immune response to these treatments will affect them.

Our research not only includes trying to understand more about how these variants affect our bodies but has led to the development of tests for these variants.

These tests can give us important information on whether someone has a high or low risk of developing cancer or has a higher risk level for side effects from certain cancer treatments. A patient, with their doctor, can then use this information to tailor a person-specific treatment plan, either by better prevention or by choosing treatments that are the safest for the patient.

bottom-right-heavy-curve

The KRAS-variant

The KRAS-variant was the first noncoding variant found to be involved with cancer and identifies people at higher risk of cancers of the breast, ovaries, lungs, gallbladder, and chronic lymphocytic leukemia (CLL). Through past research, we have discovered how this variant affects your risk of developing these cancers and how to help mitigate those risks.

We also found that cancer drugs can affect people who carry the KRAS-variant differently. Certain types of medications work better than others for KRAS-variant patients.

For example, one study found that a chemotherapy drug called Cisplatin does not work well for those who carry the KRAS-variant.42 Other research shows a certain type of targeted cancer drug, Cetuximab, works better for them.

Find out if you carry the KRAS-variant by access testing through MiraKind →

Prostate Cancer

PROSTOXTM

PROSTOX is a genetic test for prostate cancer patients to determine if they carry certain noncoding variants in their DNA. Based on extensive research, carrying these variants predicts an increased risk of developing long-term side effects from radiation of the prostate, called GU toxicity.

Unfortunately, it's not just the tumor that receives the radiation, other tissues in the area are also affected, as radiation must pass through them to get to the prostate. These effects often translate into different types of negative side effects. Long-term genitourinary side effects can include - frequency and/or urgency of urination, incontinence, blood in the urine, pain, narrowing of the urethra, and bladder spasms. These effects show up three to six months or later after radiation therapy and occur in 15-20% of those who receive it.

PROSTOX can help patients and their doctors know if certain treatments put them at a higher or lower risk of developing these long-term side effects. With this information, the treatment plan can be tailored to reduce the risk of these side effects.

Prostate cancer patients can access PROSTOX through MiraKind →

Past research always points the way for future research. While PROSTOX is excellent at predicting late GU effects from radiation we are continuing to apply these noncoding variants to other areas treated with radiation, as well as to other cancer treatments that have unwanted side effects.

Immunotherapy treatments

PrevIOTOX

Immunotherapy, or the use of your body's immune system to treat cancer is an idea that has been pursued for hundreds of years. It wasn't until the 1980s when technology and scientific knowledge reached a certain point, that modern immunotherapy was born. As with all cancer treatments, there are risks to using immunotherapy, but with immunotherapy, they are more common and can be life-altering. These side effects are called Immune-Related Adverse Events (irAEs). The rate of irAEs can be as high as 50%.

irAEs arise when the treatment causes the immune system to attack other parts of the body, aside from the cancer.

One research area we study focuses on noncoding genetic variants that can predict the risk of developing irAEs. We found that these variants predict a 9-fold increased risk of developing irAEs. Using our research, we developed PrevIOTOX - a panel genetic test for anyone diagnosed with cancer and considering either anti-PD1 or anti-PDL1 immunotherapy.

PrevIOTOX will provide information on whether you have an increased risk of developing irAEs from immunotherapy. Knowing your risk level could help you and your doctor make the safest treatment decision.

Cancer patients can access PrevIOTOX through MiraKind →

bottom-up-left-heavy-curve
bottom-right-heavy-curve

sign up for updates

The world of genetics and medicine continues to evolve. Education is one of the foundations of MiraKind. We will provide you regular updates in an easily digestible format.

curve-up2

Disclaimer

Any discussion of medical management options on this website is for general informational purposes only and does not constitute a medical recommendation. All medical management decisions should be made based on consultation between each patient and his or her healthcare professional.

arrow up to top